Browse News

Found 140 articles

• 

  Biopharma Layoff Tracker 2023: NightHawk, Fresh Tracks, Histogen and More Cut...

  9/21/2023

  Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.

• Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film

  9/20/2023

  Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided an update on the development timeline and pathway for its oral epinephrine product candidate, Anaphylm™.

• enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer

  9/7/2023

  enGene, Inc. announced the appointment of Richard Bryce, MBChB, MRCGP, MFPM as its Chief Medical Officer, effective September 19, 2023.

• Precision Oncology Market Size is Projected to Reach USD 2,58,350 Million By 2032

  8/17/2023

  The global precision oncology market size is estimated to grow from USD 1,00,060 million in 2022 to reach around USD 2,58,350 million by 2032, growing at a CAGR of 9.9% from 2023 to 2032, A study published by Towards Healthcare.

• Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update

  8/10/2023

  Rain Oncology Inc., reports financial results for the second quarter ended June 30, 2023, and provides a corporate update.

• Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

  8/7/2023

  Provectus announced that preclinical data from ongoing research on investigational cancer immunotherapy PV-10 as an immune vaccine adjuvant will be presented on a poster presentation at the Society for Immunotherapy of Cancer 2023 annual meeting to be held in San Diego, CA from November 1-5.

• Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2023 Congress

  8/1/2023

  Provectus (OTCQB: PVCT) today announced that data from ongoing clinical trials of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the combination therapy treatments of uveal melanoma metastatic to the liver (NCT00986661) and Stage III-IV cutaneous melanoma (NCT02557321) will be presented on two poster presentations at the Society for Melanoma Research (SMR) 2023 Congress (the SMR annual meeting) to be held in Philadelphia, PA.

• Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ (epinephrine) Sublingual Film

  7/27/2023

  Aquestive Therapeutics, Inc. today released topline data from its latest clinical crossover pilot trial, Study AQ109103 (the “103 study”), for Anaphylm™ (epinephrine) Sublingual Film.

• Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023

  7/26/2023

  Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023.

• Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference

  7/25/2023

  Aquestive Therapeutics, Inc. today announced that two posters recapping the positive topline data from pharmacokinetic (PK) and pharmacodynamic (PD) studies of Anaphylm epinephrine sublingual film will be presented at the Aspen Allergy Conference, which will be held from July 30 – August 3 in Aspen, CO.

• Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at Global Food Allergy Prevention Summit

  7/6/2023

  Aquestive Therapeutics, Inc. today announced that two posters recapping the positive data from pharmacokinetic and pharmacodynamic studies of Anaphylm epinephrine sublingual film will be presented at the Global Food Allergy Prevention Summit (GFAPS 2023), which will be held from July 7-9 in Chicago, IL.

• Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment

  6/29/2023

  Aquestive Therapeutics, Inc. today provided an update on recent business developments and announced the appointment of Carl N. Kraus, M.D. as Chief Medical Officer of the Company.

• Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study

  5/31/2023

  Aquestive Therapeutics, Inc. released topline clinical data from recent pilot studies that were completed following the End-of-Phase 2 meeting with the FDA.

• Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs

  5/30/2023

  Rain Oncology Inc., a clinical stage company developing precision oncology therapeutics announced an update to its clinical strategy for milademetan, its small molecule inhibitor of the MDM2-p53 complex, to optimize Company resources.

• Medicines360 Appoints Andrea Olariu, MD, PhD as Chief Executive Officer

  5/30/2023

  Medicines360, a mission-driven nonprofit women's health pharmaceutical organization, announced that its Board of Directors has named Andrea Olariu, MD, PhD as Chief Executive Officer, effective immediately.

• Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)

  4/20/2023

  Aquestive Therapeutics, Inc. today announced the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name Anaphylm™ as the proposed brand name for AQST-109, the Company’s polymer matrix-based epinephrine prodrug administered as a sublingual film in development for the treatment of severe allergic reactions including anaphylaxis.

• Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

  2/21/2023

  Aquestive Therapeutics, Inc. today announced that four late breaking posters recapping the positive data from pharmacokinetic and pharmacodynamic studies of AQST-109 epinephrine sublingual film will be presented at the American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting, which will be held from February 24-27 in San Antonio, Texas.

• Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives

  1/6/2023

  Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today provided an update on recent business developments and outlined key 2023 objectives.

• Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)

  12/22/2022

  Aquestive Therapeutics, Inc. today announced the completion of its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (“FDA”) for AQST-109 (epinephrine sublingual film) for the treatment of severe allergic reactions including anaphylaxis.

• Cracking the mystery behind a deadly brain cancer

  12/21/2022

  The brain cancer, glioblastoma, is a fierce and formidable opponent. Its millions of victims include Senator John McCain, President Biden's son, Beau, and famed film critic Gene Siskel, to name just a few.